logo
Goldman Sachs Weighs In on Tesla Stock; Examines FSD Prospects in China

Goldman Sachs Weighs In on Tesla Stock; Examines FSD Prospects in China

Tesla (NASDAQ:TSLA) stock could get a major lift if it pulls off a successful rollout of its FSD (full self-driving) software in China. With the country's massive auto market, intensifying race in autonomous tech, and the profit potential of AI-driven products, FSD could become a cornerstone of Tesla's future valuation.
Protect Your Portfolio Against Market Uncertainty
That, in any case, is the view of Goldman Sachs' 5-star analyst, Mark Delaney, who emphasizes that China hasn't just become a focal point for Tesla's autonomous ambitions – it's also grown into the company's largest market for new vehicle sales over the past year.
This shift isn't surprising given both the size of the Chinese market and the country's relatively high adoption of battery electric vehicles (BEVs). But Delaney also attributes it to evolving market dynamics. Tesla's share of the U.S. BEV market has slipped to around 45% as of Q1, and its presence in Europe has fallen to the low double digits. In contrast, its market share in China has remained relatively stable, holding in the high single digits.
That backdrop makes Tesla's recent FSD progress in China all the more significant. In late February, media reports revealed that the company had rolled out FSD upgrades to some local users who had purchased its ¥64,000 ($8,750 USD) software package, adding capabilities like lane changes, traffic light recognition, and turning. During the Q1 earnings call, Tesla confirmed it launched a supervised version of FSD in China using its existing generalized software with minimal localized data.
While the system has historically performed better in the U.S. due to richer datasets, early reviews from China suggest promising performance, though some glitches, particularly around lane usage and traffic rules, remain. According to Delaney, these issues likely stem from the 'more limited' data available for the Chinese market.
Tesla's FSD, however, is just one of several ADAS options available to consumers in China, where many local competitors include similar features as standard on mainstream vehicles.
'The level of technology and cost improvement that Tesla can achieve with FSD, both absolute and relative to competitors, will be key for its longer-term economics related to autonomy in our opinion (both globally and in China),' Delaney opined.
Tesla aims to launch robotaxi services in Texas in June, with plans to expand over time. In the U.S., Tesla's vehicle costs could give it an edge over other robotaxi options, provided its technology reaches the required level for deployment. In Q1, Tesla's cost of goods sold (COGS) per vehicle was about $35.5K, and its newer HW4-equipped vehicles have the hardware necessary for Level 4 autonomy. If Tesla expands robotaxi operations to China, it will face a different competitive environment, with several autonomous vehicles offering attractive costs.
'We believe technology development, scale/cost, and regulatory approvals will be key factors to monitor to assess Tesla's success with robotaxis in the region,' the analyst went on to add.
Down to business, what does this all mean for investors? Despite the excitement around FSD and robotaxis, Delaney, who's ranked in the top 3% of stock pros on TipRanks, isn't ready to jump on the bullish bandwagon just yet. The analyst rates Tesla shares a Neutral, while his $235 price target implies the stock is overvalued by 26%. (To watch Delaney's track record, click here)
9 other analysts are also on the fence here and with an additional 16 Buys and 11 Sells, the analyst consensus rates Tesla stock a Hold. Going by the $284.23 average price target, shares will drop ~11% from current levels. (See TSLA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Verint Genie Bot Delivers Millions of Dollars in Business Value
Verint Genie Bot Delivers Millions of Dollars in Business Value

Yahoo

time31 minutes ago

  • Yahoo

Verint Genie Bot Delivers Millions of Dollars in Business Value

MELVILLE, N.Y., June 12, 2025--(BUSINESS WIRE)--Verint® (NASDAQ: VRNT), The CX Automation Company™, today announced AI business outcomes customers achieved with the recently launched Verint Genie Bot. Part of Verint Open Platform's business analytics solutions, Verint Genie Bot is supercharging business analyst capacity. The bot delivers critical customer experience (CX) insights to executives at unprecedented speed across customer complaints, churn, upsell opportunities and cost reduction initiatives. Verint Genie Bot Delivers Powerful AI Business Outcomes The AI-powered bot delivers actionable CX insights in minutes, driving millions of dollars in value to customers across industries. For example, in the first day of using Verint Genie Bot, an international financial institution uncovered the insights to optimize customer journeys, reduce costs and increase revenue by $5 million. In addition, an energy provider leveraged the bot's insights to streamline self-service and agent workflows, opening the door to $3 million in cost reduction. "Our latest release of Verint Genie Bot is another breakthrough in applying agentic AI to CX Automation," said Verint's Global Vice President, Product and Go-to-Market Strategy, Daniel Ziv. "By combining the latest generative and agentic AI capabilities, Verint Genie Bot is now proven to create unparalleled value." Discover how Verint Genie Bot and Verint Open Platform can unlock transformative insights and AI outcomes, now. About Verint Verint® (NASDAQ: VRNT) is a leader in Customer Experience (CX) Automation, serving a customer base that includes more than 80 of the Fortune 100 companies. The world's most iconic brands use the Verint Open Platform and our team of AI-powered bots to deliver tangible AI Business Outcomes, Now™ across the enterprise. Verint is uniquely positioned to help brands increase CX Automation with our differentiated, AI-powered Open Platform. Verint, The CX Automation Company™, is proud to be Certified™ by Great Place To Work®. Learn more at This press release contains "forward-looking statements," including statements regarding expectations, predictions, views, opportunities, plans, strategies, beliefs and statements of similar effect relating to Verint Systems Inc. These forward-looking statements are not guarantees of future performance and they are based on management's expectations that involve a number of risks, uncertainties and assumptions, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. For a detailed discussion of these risk factors, see our Annual Report on Form 10-K for the fiscal year ended January 31, 2025, and other filings we make with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release and, except as required by law, Verint assumes no obligation to update or revise them or to provide reasons why actual results may differ. VERINT, VERINT DA VINCI, VERINT OPEN CCAAS, THE CX AUTOMATION COMPANY, THE CUSTOMER ENGAGEMENT COMPANY AND THE ENGAGEMENT CAPACITY GAP are trademarks of Verint Systems Inc. or its subsidiaries. Verint and other parties may also have trademark rights in other terms used herein. View source version on Contacts Media Relations Andi Investor Relations Matthew Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Artificial Intelligence in Medicine Market to Reach USD 45 Billion by 2034
Artificial Intelligence in Medicine Market to Reach USD 45 Billion by 2034

Yahoo

time31 minutes ago

  • Yahoo

Artificial Intelligence in Medicine Market to Reach USD 45 Billion by 2034

Artificial Intelligence in Medicine Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- The global Artificial Intelligence (AI) in Medicine Market is undergoing a remarkable transformation, spurred by rapid technological advancements and the growing need for efficient, accurate healthcare delivery. As of 2024, the market is valued at approximately USD 16.5 billion, and it is projected to reach nearly USD 45 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 12.5%. This expansion reflects the increasing integration of AI technologies into various healthcare applications, from diagnostics to treatment and patient management. Download PDF Brochure: AI is revolutionizing the healthcare landscape by enabling predictive analytics, enhancing decision-making, and reducing human error in clinical processes. Applications such as virtual nursing assistants, AI-based imaging diagnostics, and drug discovery platforms are at the forefront of this evolution. However, despite its promising trajectory, the sector must overcome several challenges, including high implementation costs, data privacy concerns, and regulatory complexities. Market Segmentation and Key Applications The AI in medicine market is segmented across multiple dimensions, including application, product type, end-user, technology, deployment model, and region. Application-wise, the market covers: Clinical Data & Workflow Management: This segment leverages AI to enhance hospital operations by organizing patient records, streamlining clinical workflows, and reducing administrative burden. The increasing complexity and volume of patient data are driving investments in AI-powered workflow management systems. Medical Imaging & Diagnostics: One of the largest and fastest-growing segments, AI tools in imaging help radiologists detect abnormalities with higher accuracy and speed. With deep learning algorithms improving diagnostic precision, this segment currently represents 27% of the market, equivalent to approximately USD 4.4 billion. Virtual Nursing Assistants: These AI-enabled systems offer round-the-clock patient monitoring, medication reminders, and chronic disease management solutions, making them vital tools in reducing hospital readmissions and improving patient engagement. Drug Discovery & Development: AI significantly shortens drug development timelines by analyzing large datasets to identify potential compounds and predict clinical trial outcomes, an essential capability in a highly competitive pharmaceutical sector. Personalized Medicine and Predictive Analytics are also emerging as high-potential application areas, offering tailored treatment plans and proactive health management tools based on individual patient data. Technologies Driving Innovation The technological foundation of AI in medicine lies in advanced capabilities such as Machine Learning (ML) and Natural Language Processing (NLP). Machine Learning (ML) is the engine behind many applications, offering predictive power through data analysis. It enables tools for early disease detection, personalized treatment, and healthcare automation. Natural Language Processing (NLP) helps extract insights from unstructured clinical data, enhancing the accuracy of clinical documentation and patient communication. Machine Vision is another essential technology, particularly in medical imaging, allowing high-resolution image interpretation for diagnostics. Robotics is gaining traction in AI-assisted surgeries, providing greater precision and reducing recovery times for patients. Product Types and Deployment Models AI in medicine is categorized by product type into software, hardware, and services. Software solutions dominate the market, encompassing tools for diagnostics, data management, imaging, and patient care. These products are widely adopted due to their flexibility, scalability, and integration with existing systems. Services, including consulting, implementation, and technical support, are crucial for helping institutions transition smoothly into AI-powered systems. Hardware solutions such as AI-embedded medical devices and servers are also gaining popularity, especially in large hospitals and diagnostic labs. Deployment is mainly split between on-premise and cloud-based models. While traditional on-premise systems still have a foothold, cloud-based solutions are rapidly gaining market share due to lower costs, ease of implementation, and enhanced collaboration capabilities. Browse full Report - Key End Users and Their Impact The major end users in the AI in medicine market include: Hospitals, which account for around 40% of the total market share. These institutions are leading adopters of AI, utilizing it to optimize clinical decision-making, reduce operational costs, and enhance patient outcomes. Pharmaceutical Companies are employing AI to boost research and development efficiency, improve market intelligence, and shorten drug discovery cycles. Diagnostic Laboratories benefit from AI through faster and more accurate test results, contributing to better disease management. Other significant users include research organizations and healthcare IT firms, both of which play critical roles in developing and deploying new AI technologies. Market Segmentation By Application - Clinical Data & Workflow Management - Medical Imaging & Diagnostics - Virtual Nursing Assistants - Drug Discovery & Development - Personalized Medicine - Predictive Analytics - Remote Monitoring - Robotic Surgery By End-User - Hospitals - Pharmaceutical Companies - Diagnostic Laboratories - Research Organizations - Healthcare IT Companies By Technology - Natural Language Processing (NLP) - Machine Learning (ML) - Machine Vision - Robotics By Product Type - Hardware - Software - Services By Deployment Model - On-Premise - Cloud-Based By Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Buy Now: Regional Insights and Opportunities Geographically, North America leads the global market, contributing around 44% of revenue in 2024. This leadership stems from the presence of advanced healthcare infrastructure, high adoption rates of new technologies, and robust R&D initiatives supported by government funding. Europe holds a 30% market share, driven by proactive regulatory policies and increasing adoption of digital health tools. Countries like Germany, the UK, and France are at the forefront of AI innovation in healthcare. The Asia-Pacific region, currently at 20% market share, is expected to witness the fastest growth with a CAGR of 32%. Rapid urbanization, population growth, and rising investments in healthcare technology—especially in China and India—are propelling this expansion. Latin America and the Middle East & Africa (MEA) are emerging markets, where mobile health applications and increasing healthcare access are creating favorable conditions for AI adoption, despite ongoing infrastructure and regulatory challenges. Market Drivers and Challenges Several key factors are fueling the growth of the AI in medicine market: Demand for Efficient Healthcare: The growing burden of chronic diseases and increasing patient loads are compelling healthcare providers to seek AI-driven efficiencies. Rising Volume of Healthcare Data: The digitization of medical records and use of electronic health records (EHRs) have created a vast pool of data, ideal for AI analysis. Advancements in AI Capabilities: Improvements in AI algorithms and computing power are allowing for more sophisticated medical applications. However, challenges persist: Data Privacy and Security: The use of sensitive patient information in AI systems raises significant privacy concerns, necessitating strict compliance with data protection regulations. High Implementation Costs: Small and mid-sized organizations may find it difficult to invest in AI infrastructure without clear short-term returns. Regulatory Complexity: The lack of standard global regulations for AI in healthcare can hinder innovation and delay product approvals. Emerging Trends and Future Outlook Several trends are expected to shape the future of AI in medicine: Personalized Medicine is gaining traction, with AI being used to tailor treatments based on a patient's genetic, lifestyle, and environmental factors. Telemedicine Integration: AI tools are increasingly being embedded in virtual care platforms to enhance diagnosis, monitoring, and patient interaction. Collaborative Ecosystems: Partnerships between tech giants and healthcare institutions are accelerating innovation and expanding the market. New Business Models: Subscription-based AI platforms and AI-as-a-Service (AIaaS) offerings are emerging, making advanced solutions accessible to a broader range of providers. Key Competitors IBM Watson Health Siemens Healthineers Philips Healthcare Google Health GE Healthcare Microsoft Healthcare Cerner Corporation Allscripts Healthcare Solutions Medtronic Oracle Health Sciences NVIDIA OpenAI Zebra Medical Vision Tempus PathAI Recent Market Developments 1. IBM Watson Health - Month/Year: March 2023 - Type of Development: Strategic Partnership - Detailed Analysis: In March 2023, IBM Watson Health announced a strategic partnership with Merck to leverage AI in drug development. This alliance aims to improve the efficiency of clinical trials by integrating AI-driven insights into the research workflow. The significance of this development lies in the potential to expedite the drug discovery process, reducing time-to-market and costs associated with traditional methods. This partnership exemplifies a growing trend of collaborative ecosystems involving technology firms and pharmaceutical companies. It is likely to shift the competitive landscape as more companies seek to incorporate AI for similar purposes, enhancing the speed and efficacy of bringing innovative treatments to patients. 2. Siemens Healthineers - Month/Year: July 2023 - Type of Development: Product Launch - Detailed Analysis: Siemens Healthineers unveiled their latest AI-based imaging platform in July 2023, designed to enhance diagnostic accuracy and workflow efficiency in radiology. The introduction of this advanced software epitomizes a significant technological advancement in the medical imaging sector. With features like automated anomaly detection and real-time decision support, this platform positions Siemens at the forefront of AI integration in clinical practice. The development is likely to heighten competition among imaging technology providers and set new standards for diagnostic tools, as healthcare providers increasingly recognize the advantages of incorporating AI for improved patient outcomes. 3. Google Health - Month/Year: August 2023 - Type of Development: Regulatory Approval - Detailed Analysis: In August 2023, Google Health received FDA approval for its AI algorithms that assist in identifying retinal diseases from eye scans. This regulatory milestone marks a crucial turning point in the acceptance of AI technologies within the healthcare sector. The significance of this development extends beyond Google's advancements; it reflects a broader movement towards regulatory bodies embracing AI solutions for enhancing diagnostic accuracy. This approval legitimizes the application of AI in critical healthcare areas and could lead to increased investments in AI technology among key players, promoting a competitive edge in diagnostics for companies that can secure similar approvals. 4. Philips Healthcare - Month/Year: September 2023 - Type of Development: Acquisition - Detailed Analysis: In September 2023, Philips Healthcare acquired an AI analytics startup specializing in predictive analytics for patient care. This acquisition is significant as it strengthens Philips' portfolio in the burgeoning field of predictive healthcare technologies. By incorporating advanced AI analytics capabilities, Philips positions itself to offer more comprehensive solutions that enhance patient management and outcomes. This move is indicative of a broader trend where established players are seeking to integrate AI capabilities through acquisitions, thereby reshaping competitive dynamics within the healthcare technology landscape. It further signals to other companies the urgency to innovate and adopt AI to remain competitive. 5. Microsoft Healthcare - Month/Year: October 2023 - Type of Development: Technological Advancement - Detailed Analysis: In October 2023, Microsoft Healthcare launched a new generative AI model aimed at improving patient engagement through personalized communication. This technological advancement utilizes large language models to tailor interactions with patients, providing them with timely and relevant information. The significance of this development cannot be overstated, as it represents a shift toward using AI for enhancing patient experience and adherence to treatment regimes. This innovation is likely to set a new trend in patient-centric care models, compelling competitors to invest in similar technologies. Furthermore, the emphasis on personalization in healthcare could catalyze a competitive race to enhance patient engagement, transforming traditional approaches to communication in the sector. This report is also available in the following languages : Japanese (医療市場における人工知能), Korean (의학 시장의 인공지능), Chinese (医药市场中的人工智能), French (L'intelligence artificielle sur le marché médical), German (Künstliche Intelligenz im Medizinmarkt), and Italian (Intelligenza artificiale nel mercato della medicina), etc. Request Sample Pages: More Research Finding – Hot Flashes Treatment Market The hot flashes treatment market is valued at approximately $2.1 billion in 2024, driven by rising menopausal awareness and the increasing acceptance of hormone replacement therapy (HRT). By 2034, the market is projected to reach around $3.6 billion, suggesting sustained growth fueled by an expanding elderly population and a growing preference for non-hormonal treatments. Cancer Nanomedicine Market The cancer nanomedicine market is valued at approximately $72 billion in 2024, with an anticipated growth trajectory that will elevate its market value to around $150 billion by 2034. This reflects a Compound Annual Growth Rate (CAGR) of approximately 7.6% during the forecast period from 2025 to 2034. Sodium Bicarbonate Medicine Market The sodium bicarbonate medicine market is projected to hold a value of approximately $580 million in 2024, with an anticipated rise to $1.1 billion by 2034. This growth signifies a Compound Annual Growth Rate (CAGR) of around 6.7% from 2025 through 2034. Gecko Dingchuan Wan Market The global market value for Gecko Dingchuan Wan is estimated at approximately $150 million, reflecting a robust demand for traditional Chinese medicine products. The market is poised for growth, with a projected value of around $300 million by 2034. This equates to a Compound Annual Growth Rate (CAGR) of approximately 7.2% during the forecast period of 2025 to 2034. Full Suture Anchor Market The global full suture anchor market is projected to reach a value of approximately $1.2 billion in 2024, driven by increasing demands in orthopedic surgeries, particularly in shoulder and knee repairs. The market is anticipated to expand significantly, with a projected value of around $2.0 billion by 2034, reflecting robust growth trends. Sports Medicine Consumables Market The global sports medicine consumables market is valued at approximately $6.5 billion in 2024, with projections indicating significant growth, potentially reaching $11.2 billion by 2034. This growth trajectory translates to a Compound Annual Growth Rate (CAGR) of around 6.5% over the forecast period from 2025 to 2034. Rotary Cell Culture System RCCS Market The global Rotary Cell Culture System (RCCS) market is valued at approximately $300 million in 2024. This market is projected to grow to around $750 million by 2034, driven by advancements in biopharmaceutical production and regenerative medicine. The expected Compound Annual Growth Rate (CAGR) during the forecast period of 2025–2034 is estimated at 9.5%. Huoxiang Zhengqi Drug Market The Huoxiang Zhengqi Drug market is projected to reach approximately $1.2 billion in 2024, driven by the growing demand for traditional Chinese medicine (TCM) and an increased awareness of holistic health solutions. Over the forecast period from 2025 to 2034, market value is expected to expand significantly, reaching an estimated $2.5 billion by 2034. This indicates a robust Compound Annual Growth Rate (CAGR) of around 8.5%. Klinefelter Syndrome Treatment Market The Klinefelter Syndrome treatment market is projected to reach a value of approximately $450 million in 2024, with a growth trajectory leading to an estimated market value of $850 million by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 6.5% during the forecast period of 2025 to 2034. Alternative Cancer Treatment Market The alternative cancer treatment market is valued at approximately $20 billion in 2024 and is projected to reach around $40 billion by 2034. This forecast reflects a robust Compound Annual Growth Rate (CAGR) of 7.3% during the period from 2025 to 2034, driven by increasing consumer demand for holistic approaches and complementary therapies alongside conventional treatments. Platelet Kit Market The global platelet kit market is valued at approximately $3.2 billion, reflecting a robust demand driven by increasing applications in surgical procedures and rising incidences of chronic diseases. The market is projected to reach around $5.8 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2025 to 2034. Cardiac Troponin I ELISA Test Kit Market The global market for Cardiac Troponin I ELISA Test Kits is valued at approximately $500 million in 2024, driven by the increasing prevalence of cardiovascular diseases and the growing demand for rapid diagnostic tools in clinical settings. The market is projected to reach around $830 million by 2034, reflecting a robust growth trajectory supported by advancements in diagnostic technologies and a rising awareness of cardiac health Myoglobin ELISA Test Kit Market The Myoglobin ELISA Test Kit market is projected to be valued at approximately $120 million in 2024, driven by increasing incidences of myocardial infarction and the rising demand for early diagnosis of cardiac conditions. The market is expected to witness robust growth, with a projected value reaching around $210 million by 2034, reflecting significant advancements in diagnostic technologies and growing healthcare infrastructure in emerging markets. Anesthesia Supply Market The global anesthesia supply market is valued at approximately $15 billion. The market is projected to witness significant growth, with an estimated value of $22 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of around 5.5% during the forecast period from 2025 to 2034. Chinese Medicine Formula Granules Market The Chinese Medicine Formula Granules market is poised for significant growth, with a current estimated market value of approximately USD 3.2 billion in 2024. Projections indicate a robust expansion, anticipating a market value of around USD 6.5 billion by 2034. This represents a compound annual growth rate (CAGR) of 7.4% during the period from 2025 to 2034. Potential Therapy Equipment Market The global market for potential therapy equipment is valued at approximately $18 billion. The market is poised for significant growth, with projections estimating a market value of around $32 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of approximately 6.0% during the forecast period from 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

What the market may have to say about Trump's unilateral tariffs
What the market may have to say about Trump's unilateral tariffs

Yahoo

time31 minutes ago

  • Yahoo

What the market may have to say about Trump's unilateral tariffs

President Trump stated that he plans to install unilateral tariff rates for trading partners in two weeks. This comes after the administration touted a trade deal with China on Wednesday, including a 55% tariff on Chinese imports, that the two nations' leaders still have to agree upon. Charles Schwab senior investment strategist Kevin Gordon sits down with Brad Smith about how markets (^DJI, ^IXIC, ^GSPC) have been reacting in this tariff saga and how these themes have fed into the economy and GDP figures. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store